Pretreatment with P2Y12 inhibitors in non-ST-Segment-elevation acute coronary syndrome: an outdated and harmful strategy.
From the Institut de Cardiologie, Centre Hospitalier Universitaire Pitié-Salpêtriėre (ACTION Study Group, AP-HP, Université Paris 6), Paris, France (J.-P.C., J.S., and G.M.); and Department of Cardiology, Hospital La Fontonne, Antibes, France (A.B.-A.). jean-philippe.collet@psl.aphp.fr.
Jean-Philippe
JP
Collet
From the Institut de Cardiologie, Centre Hospitalier Universitaire Pitié-Salpêtriėre (ACTION Study Group, AP-HP, Université Paris 6), Paris, France (J.-P.C., J.S., and G.M.); and Department of Cardiology, Hospital La Fontonne, Antibes, France (A.B.-A.).
Johanne
J
Silvain
From the Institut de Cardiologie, Centre Hospitalier Universitaire Pitié-Salpêtriėre (ACTION Study Group, AP-HP, Université Paris 6), Paris, France (J.-P.C., J.S., and G.M.); and Department of Cardiology, Hospital La Fontonne, Antibes, France (A.B.-A.).
Anne
A
Bellemain-Appaix
From the Institut de Cardiologie, Centre Hospitalier Universitaire Pitié-Salpêtriėre (ACTION Study Group, AP-HP, Université Paris 6), Paris, France (J.-P.C., J.S., and G.M.); and Department of Cardiology, Hospital La Fontonne, Antibes, France (A.B.-A.).
Gilles
G
Montalescot
D054058:Acute Coronary Syndrome / Q000175:diagnosis / Q000188:drug therapy*; D000241:Adenosine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006470:Hemorrhage / Q000139:chemically induced / Q000175:diagnosis; D006801:Humans; D058921:Purinergic P2Y Receptor Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000077486:Ticagrelor; D016896:Treatment Outcome
D058921:Purinergic P2Y Receptor Antagonists; D000077486:Ticagrelor; D000241:Adenosine